The first pilot study from India analyzing COVAXIN – COVISHEILD mixed doses The third COVID-wave led by the Omicron variant has started in India. Although the initial data indicates that this wave will be milder than the previous Delta one with less hospitalization, still a large
The decision regarding enhancing interval between two doses of Covishield was based on scientific evidence and taken in a transparent manner, NTAGI Chair N K Arora said on Tuesday. There was no dissenting voice among the members of the National Technical Advisory Group on Immunization (NTAGI
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
